Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI322 in advanced malignant tumors
NCT04338659Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jan 2021
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simridarlimab in solid tumor (advanced stage) and lymphoma, sponsored by Innovent Biologics. Primary endpoints: Dose Limiting Toxicity and Treatment-related Adverse Events. Started Jan 2021; status: completed.
02
Drugs
simridarlimab
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT04338659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338659.